Lifeward Ltd. (NASDAQ: LFWD) filed a Current Report on Form 8-K dated September 8, 2026, to disclose an updated investor presentation. The document provides an overview of the company’s commercial platform, financial performance, and future product pipeline.
According to the filing, Lifeward reported $21.8 million in revenue over the trailing 12 months ending June 30, 2026, representing a 16% increase compared to the same period in 2025. The company reported $11 million in cash as of June 30, 2026.
The presentation outlines a strategy focused on a single commercial platform to scale rehabilitation technology. Lifeward’s current portfolio includes the ReWalk powered exoskeleton for spinal cord injury and the AlterG anti-gravity rehabilitation system. The company claims to have deployed over 7,000 units across 37 countries and has established reimbursement access for approximately 46% of Medicare Advantage enrollees.
The company detailed a roadmap for internal product development and acquisitions. Lifeward anticipates launching the StrideSense platform in 2027, followed by an upper-body powered exoskeleton in 2028. The presentation lists a future addressable market (TAM) of $24 billion.
Lifeward also highlighted a strategic partnership with Oramed Pharmaceuticals Inc., through which it acquired the Protein Oral Delivery (POD) platform and the oral insulin candidate ORMD-0801. The company stated that the POD program is pre-funded by Oramed and requires minimal management oversight.
